WO2013037809A1 - Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors - Google Patents
Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors Download PDFInfo
- Publication number
- WO2013037809A1 WO2013037809A1 PCT/EP2012/067810 EP2012067810W WO2013037809A1 WO 2013037809 A1 WO2013037809 A1 WO 2013037809A1 EP 2012067810 W EP2012067810 W EP 2012067810W WO 2013037809 A1 WO2013037809 A1 WO 2013037809A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- methyl
- oxo
- triazolo
- alkyl
- Prior art date
Links
- CGGKXTLQGBXILT-UHFFFAOYSA-N CC(N(C(N1C2c(cc3)ccc3C#N)=NN(C)C1=O)c1cc(C(F)(F)F)ccc1)=C2C(OC)=O Chemical compound CC(N(C(N1C2c(cc3)ccc3C#N)=NN(C)C1=O)c1cc(C(F)(F)F)ccc1)=C2C(OC)=O CGGKXTLQGBXILT-UHFFFAOYSA-N 0.000 description 1
- LVHFQHJUMYFCKS-UHFFFAOYSA-N CC(N(C(N1C2c(cc3)ccc3C#N)=NN(CCCS(CCC[N](C)(C)C)(=O)=O)C1=O)c1cc(C(F)(F)F)ccc1)=C2C#N Chemical compound CC(N(C(N1C2c(cc3)ccc3C#N)=NN(CCCS(CCC[N](C)(C)C)(=O)=O)C1=O)c1cc(C(F)(F)F)ccc1)=C2C#N LVHFQHJUMYFCKS-UHFFFAOYSA-N 0.000 description 1
- 0 CC(N(C(N1C2c(cc3)ccc3C#N)=NNC1=O)c1cc(C(F)(F)F)ccc1)=C2C(**)=O Chemical compound CC(N(C(N1C2c(cc3)ccc3C#N)=NNC1=O)c1cc(C(F)(F)F)ccc1)=C2C(**)=O 0.000 description 1
- OMKNLOSPFHQIMT-UHFFFAOYSA-N CC(N(C(N1C2c(cc3)ccc3C#N)=NNC1=O)c1cc(C(F)(F)F)ccc1)=C2C(OCCN(C)C)=O Chemical compound CC(N(C(N1C2c(cc3)ccc3C#N)=NNC1=O)c1cc(C(F)(F)F)ccc1)=C2C(OCCN(C)C)=O OMKNLOSPFHQIMT-UHFFFAOYSA-N 0.000 description 1
- UUOYZBNOVQLSFA-HXUWFJFHSA-N CC(N(C(N1[C@@H]2c(cc3)ccc3C#N)=NN(CC(O)=O)C1=O)c1cc(C(F)(F)F)ccc1)=C2C(OC)=O Chemical compound CC(N(C(N1[C@@H]2c(cc3)ccc3C#N)=NN(CC(O)=O)C1=O)c1cc(C(F)(F)F)ccc1)=C2C(OC)=O UUOYZBNOVQLSFA-HXUWFJFHSA-N 0.000 description 1
- HQLWOAXYKHPPTQ-UHFFFAOYSA-N CC(N(C)CCCN(C(N1C(c(cc2)ccc2C#N)C(C(OC)=O)=C2C)=O)N=C1N2c1cc(C(F)(F)F)ccc1)=O Chemical compound CC(N(C)CCCN(C(N1C(c(cc2)ccc2C#N)C(C(OC)=O)=C2C)=O)N=C1N2c1cc(C(F)(F)F)ccc1)=O HQLWOAXYKHPPTQ-UHFFFAOYSA-N 0.000 description 1
- GPRWIYSADKEKNU-UHFFFAOYSA-P CC(N(c1cc(C(F)(F)F)ccc1)C(N(C1c(cc2)ccc2C#N)C(NCc2ccc(C[N+](C)(C)C)cc2)=O)=[NH2+])=C1C(OC)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(N(C1c(cc2)ccc2C#N)C(NCc2ccc(C[N+](C)(C)C)cc2)=O)=[NH2+])=C1C(OC)=O GPRWIYSADKEKNU-UHFFFAOYSA-P 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M Cc(cc1)ccc1S([O-])(=O)=O Chemical compound Cc(cc1)ccc1S([O-])(=O)=O JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- This invention relates to heterocyclic compounds, which are pyrimidine derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
- HNE Human neutrophil elastase
- HNE has been implicated in the upregulation of IL-8 gene expression and also induces IL-8 release from the epithelial cells of the lung.
- both small molecule inhibitors and protein inhibitors of HNE inhibit the inflammatory response and the development of emphysema (Wright, J.L. et al. Am. J. Respir. Crit. Care Med. 2002, 166, 954-960; Churg, A. et al. Am. J. Respir. Crit. Care Med. 2003, 168, 199-207).
- HNE may play a role both in matrix destruction and in amplifying inflammatory responses in chronic respiratory diseases where neutrophil influx is a characteristic feature.
- HNE is believed to play a role in several pulmonary diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), acute respiratory distress syndrome (A DS), pulmonary emphysema, pneumonia and lung fibrosis. It is also implicated in several cardiovascular diseases in which tissue remodelling is involved, for example, in heart failure and the generation of ischaemic tissue injury following acute myocardial infarction.
- COPD chronic bronchitis
- emphysema emphysema
- small-airway disease emphysema
- BAL bronchoalveolar leakage
- protease-anti-protease balance also known as the "elastase:anti-elastase hypothesis"
- an imbalance of HNE and endogenous antiproteases such as a 1 -antitrypsin (a AT), secretory leukocyte protease inhibitor (SLPI) and pre-elafin leads to the various inflammatory disorders of COPD.
- a AT 1 -antitrypsin
- SLPI secretory leukocyte protease inhibitor
- pre-elafin leads to the various inflammatory disorders of COPD.
- Individuals that have a genetic deficiency of the protease inhibitor al -antitrypsin develop emphysema that increases in severity over time (Laurrell, C.B.; Erikkson, S Scand. J. Clin. Invest. 1963 15, 132-140).
- the present invention addresses the above mentioned need by providing the compounds of the invention.
- This invention provides novel compounds which are inhibitors of HNE, and are useful in the treatment of diseases or conditions in which HNE activity plays a part.
- the invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:
- A is CH or N
- R is selected from:
- W is a 5-6-membered heteroaryl ring which is optionally substituted by a group -SO 2 (Ci-C 4 )alkyl;
- n 1 , 2 or 3;
- t is zero, 1 , 2 or 3;
- r is zero, 1 , 2, 3 or 4;
- R 5 is selected in the group consisting of: hydrogen, (Ci-C 6 )alkyl, (d- C 6 )alkylNR 16 R 15 and (d-d)alkylN + R 17 R 15 Ri 6 ;
- R 6 is hydrogen or (Ci-C 6 )alkyl
- R 7 is selected in the group consisting of: hydrogen, (Ci-C 6 )alkyl, carbonyl(C C 6 )alkyl, -SO 2 (C C 4 )alkyl and (C C 6 )alkyl NR 16 R 15 ;
- R 8 is hydrogen or (Ci-C 6 )alkyl
- R 7 and Rs may form together with the nitrogen atom to which they are attached a (C 5 -C 7 )heterocycloalkyl ring system which is optionally substituted by one or more groups (Ci-C 6 ) alkyl and oxo;
- R 16 is hydrogen or (Ci-C 6 )alkyl
- R 15 is hydrogen or (Ci-C 6 )alkyl
- R 17 is hydrogen or (Ci-C 6 )alkyl
- R 2 is hydrogen or -SO 2 R 4 , wherein R 4 is selected from: optionally substituted (Ci-C 6 )alkyl, (Ci-C 6 -alkyl)hydroxyl, amino, mono- or di(Ci-C 4 )alkylamino wherein (Ci-C 4 )alkyl may be optionally substituted, optionally substituted (C 3 -C 6 )-cycloalkyl, halogen and optionally substituted phenyl;
- R 14 is a group cyano or a group -C(O)-X 3 ;
- X is a divalent group selected from: -O-, -(CH 2 )- and -NH-;
- R 3 is a group selected from:
- Alk 1 represents a (Ci-C 4 )alkylene radical and Z is:
- R 9 and Ri 0 are independently hydrogen, optionally substituted (Ci-C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloalkyl group; or, taken together with the nitrogen they are linked to, form an optionally substituted monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S;
- R n , R 12 and R i3 are each independently optionally substituted (Ci-C 6 )alkyl or optionally substituted (C 3 -C 6 )cycloalkyl group; or any two of Rn, R i2 and R i3 taken together with the nitrogen they are linked to form an optionally substituted monocyclic (C 5 - C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S and the other of Rn, R i2 and R i 3 is an optionally substituted (Ci- C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloalkyl group;
- a radical of formula -(CH 2 ) q -[Q]-(CH 2 ) p Z wherein Z is as above defined, q is an integer ranging from zero to 3, p is an integer ranging from zero to 3 and Q represents a divalent group selected from:-O-, optionally substituted phenylene, optionally substituted (C 5 -C 7 )heterocycloalkylene, optionally substituted (C 3 -C 6 )cycloalkyl and optionally substituted pyridinylene;
- Ri 5 Ri 6 Ri 7 are present, they form quaternary salts with a pharmaceutically acceptable counter ion;
- groups R 5 , R 6 , R 7 , R 8 , R15, R 16 , Rn, and n may have the same or different meanings at each occurrence, if present in more than one group;
- the invention provides a compound of formula (ID):
- A is CH or N
- R is selected from:
- n 1 , 2 or 3;
- R 5 is hydrogen or (Ci-C 6 )alkyl
- R 6 is hydrogen or (Ci-C 6 )alkyl
- R 7 is hydrogen or (Ci-C 6 )alkyl
- R 8 is hydrogen or (Ci-C 6 )alkyl
- R 2 is hydrogen or -SO 2 R 4 , wherein R 4 is selected from: optionally substituted (Ci-C 6 )alkyl, (Ci-C 6 -alkyl)hydroxyl, amino, mono- or di(Ci-C 4 )alkylamino wherein (Ci-C 4 )alkyl may be optionally substituted, optionally substituted C 3 -C 6 -cycloalkyl, halogen and optionally substituted phenyl;
- R 14 is a group cyano or a group -C(O)-XR 3 ;
- X is a divalent group selected from: -O-, -(CH 2 )- and -NH-;
- R 3 is a group selected from:
- Alk 1 represents a (Ci-C 4 )alkylene radical and Z is:
- R 9 and R 10 are independently hydrogen, optionally substituted (Ci-C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloaikyl group; or, taken together with the nitrogen they are linked to, form an optionally substituted monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S;
- R n , R 12 and R i3 are each independently optionally substituted (Ci-C 6 )alkyl or optionally substituted (C 3 -C 6 )cycloalkyl group; or any two of Rn, R i2 and R i3 taken together with the nitrogen they are linked to form an optionally substituted monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S and the other of Rn, R i2 and R i3 is an optionally substituted (Ci-C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloalkyl group;
- a radical of formula -(CH 2 ) q -[Q]-(CH 2 ) p Z wherein Z is as above defined, q is an integer ranging from zero to 3, p is an integer ranging from zero to 3 and Q represents a divalent group selected from: -O-, optionally substituted phenylene, optionally substituted (C 5 -C 7 )heterocycloalkylene, optionally substituted (C 3 -C 6 )cycloalkyl and optionally substituted pyridinylene;
- Compounds of formula (I) may be prepared in the form of salts, particularly pharmaceutically acceptable salts, N-oxides, hydrates, solvates and polymorphs thereof. Any reference to a compound herein, or reference to “compounds of the invention”, “compounds of formula (I)", and the like includes such compounds whether or not in salt, N-oxide, hydrate, solvate or polymorphic form.
- Compounds of the invention may be used in the treatment or prevention of diseases in which HNE is implicated, for example chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (A DS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.
- COPD chronic obstructive pulmonary disease
- a DS acute respiratory distress syndrome
- pulmonary emphysema smoking-induced emphysema
- cystic fibrosis for example chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (A DS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.
- compositions comprising a compound of the invention and a pharmaceutically acceptable carrier or excipient; and (ii) the use of a compound of the invention for the manufacture of a medicament for the treatment or prevention of a disease or condition in which HNE is implicated.
- (C a -C b )alkyl wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
- a 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
- (C a -C b )alkenyl wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable.
- a is 2 and b is 6, for example, the term includes, for example, vinyl, allyl, 1 - and 2-butenyl and 2-methyl-2-propenyl.
- (C a -C b )alkylphenyl refer to the above defined “(C a -C b )alkyl” radicals wherein one hydrogen atom is replaced by one a phenyl group.
- divalent (C a -C b )alkylene radical wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms as above defined and two unsatisfied valences.
- (C a -C b ) cycloalkyl refers to saturated monocyclic hydrocarbon groups containing from a to b ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- (C a -C b )heterocycloalkyl refers to monocyclic (C a -C b )cycloalkyl groups, in which at least one ring carbon atom is replaced by a heteroatom (e.g. N, NH, S or O).
- Examples of (C a -C b )heterocycloalkyl are represented by: pyrrolidinyl, thiazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl.
- (C a -C b )heterocycloalkylene refers to a divalent (C a -C b )heterocycloalkyl radical (such as for example pyrrolidinene) wherein "(C a -C b )heterocycloalkyl group is as above defined.
- heteroaryl refers to mono or bi- cyclic ring systems with 5 to 1 1 ring atoms, in which at least one ring is aromatic and in which at least one ring atom is a heteroatom (e.g. N, NH, S or O).
- Suitable 5,6-membered heteroaryl monocyclic systems include, for instance thiophene, benzene, pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridine, imidazolidine, furan radicals and the like.
- (C a -C b ) alkoxyl wherein a and b are integers, refers to straight-chained and branched alkoxy groups wherein the number of constituent carbon atoms is in the range from a to b.
- Particular alkyl groups are methoxyl, ethoxyl, n-propoxyl, isopropoxyl and t-butoxyl.
- carbonyl(C a -C b )alkyl refers to -CO(C a -C b )alkyl groups wherein the group "(C a -C b )alkyl” has the meaning above defined.
- (C a -C b )alkylhydroxyl refer to the above defined “(C a -C b )alkyl” radicals wherein one hydrogen atom is replaced by one a group -OH.
- substituted as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (Ci-C 6 )alkyl, (Ci-C 6 )alkoxyl, hydroxyl, hydroxyl-Ci-C 6 -alkyl, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy.
- substituents each of which independently may be, for example, (Ci-C 6 )alkyl, (Ci-C 6 )alkoxyl, hydroxyl, hydroxyl-Ci-C 6 -alkyl, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy.
- An “optional substituent” may be one of the foregoing substituent groups.
- salt includes base addition and acid addition salts.
- “Pharmaceutically acceptable salts” refers to derivatives of compounds of formula (I) wherein the parent compound is suitably modified by converting any of the free acid or basic group, if present, into the corresponding addition salt with any base or acid conventionally intended as being pharmaceutically acceptable.
- Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L- lysine, N-ethyl piperidine, dibenzylamine and the like.
- bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L- lysine, N-ethyl piperidine, dibenzylamine and the like.
- hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
- organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesulfonic, glutamic, lactic, and mandelic acids and the like.
- Those compounds which have quaternary nitrogen can also form quaternary salts with a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi- succinate, naphthalene-bis sulfonate, methanesulfonate, xinafoate, and the like.
- a pharmaceutically acceptable counter-ion such as chloride, bromide, acetate, formate, p-toluenesulfonate, succinate, hemi- succinate, naphthalene-bis sulfonate, methanesulfonate, xinafoate, and the like.
- the compounds of the invention may exist as enantiomers.
- the compounds according to the invention possess two or more stereogenic centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
- the present invention is directed to compounds of formula (I)', which are compounds of formula (I) as above defined where the absolute configuration of carbon (1) is that shown here below:
- the present invention is directed to compounds of formula (I)", which are compounds of formula (I) as above defined where the absolute configuration of carbon (1) is that shown herebelow:
- the absolute configuration for carbon (1) is assigned on the basis of Cahn-Ingold-Prelog nomenclature based on groups' priorities.
- A is CH.
- R 2 is hydrogen or a group -SO 2 R 4 , wherein R 4 is (Ci-C 6 )alkyl. In a preferred embodiment, R 2 is hydrogen.
- R 4 is optionally substituted (Ci-C 6 )alkyl. In another embodiment, R 4 is (Ci-C 6 )alkyl.
- R 14 is a group cyano or a group -C(O)-XR 3 . In a preferred embodiment, R 14 is a group -C(O)-XR 3.
- X is a divalent group -O- or -NH-. In another embodiment, X is a divalent -O-.
- R 3 is a group selected from:
- R 9 and R 10 are independently hydrogen, optionally substituted (Ci-C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloaikyl group; or, taken together with the nitrogen they are linked to form an optionally substituted monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S;
- R n , R 12 and R i3 are each independently optionally substituted (Ci-C 6 )alkyl or optionally substituted (C 3 -C 6 )cycloalkyl group; or any two of Rn, R i2 and R i3 taken together with the nitrogen they are linked to form an optionally substituted monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S and the other of Rn, R i2 and R i3 is an optionally substituted (Ci-C 6 )alkyl or an optionally substituted (C 3 -C 6 )cycloalkyl group.
- R 3 is a group selected from:
- Alk 1 represents a (Ci-C 4 )alkylene radical and Z is:
- R n , R 12 and R i3 are each independently (Ci-C 6 )alkyl or (C 3 -C 6 )cycloalkyl group; or any two of Rn, R i2 and R i3 taken together with the nitrogen they are linked to form a monocyclic (C 5 -C 7 )heterocyclic ring which may contain a further heteroatom selected from N, O and S and the other of Rn, R i2 and R i3 is (Ci-C 6 )alkyl or a (C 3 -C 6 )cycloalkyl group.
- R 3 is a group selected from:
- Alk 1 represents a (Ci-C 4 )alkylene radical and Z is:
- R 3 is (Ci-C 6 )alkyl.
- R 3 is a group selected from:
- Alk 1 represents a (Ci-C 4 )alkylene radical and Z is:
- X is a divalent -O-.
- Rx is hydrogen or is a group selected from: (Ci-C 6 )alkyl, (Ci-C 6 )alkylNR 7 R 8 , (Ci-C 4 )alkenyl, (C C 6 )alkyl phenyl, and a group- (CH 2 ) n CONR 5 R 6 .
- Rx is hydrogen or is a group selected from: -CH 2 (CH 2 ) n OH, -(CH 2 ) n CONR 5 R 6 , -(CH 2 ) n SO 2 NR 5 R 6 , and -CH 2 -(CH 2 ) n NR 5 SO 2 R 6 ;
- R x is hydrogen or is a group -(CH 2 ) n CONR 5 R 6 . In a still further embodiment, R x is hydrogen.
- R x selected from: hydrogen, (Ci-C 6 )alkyl, (C C 6 )alkyl NR 7 R 8 , (C C 4 )alkenyl,
- (Ci-C 6 )alkylphenyl wherein such phenyl ring is optionally substituted by a group (Ci-C 6 )alkylNRi 5 Ri 6 or by a group -(Ci-C 6 )alkylN + Ri 5 Ri 6 Ri 7 , -(CH 2 ) n CONR 5 R 6 , -CH 2 -(CH 2 ) n NR 5 SO 2 R 6 ,, -(CH 2 ) t -(C 6 H 4 )-SO 2 (CrC 4 )alkyl, (CH 2 ) r SO 2 (Ci-C 4 )alkyl wherein such (Ci-C 4 )alkyl is optionally substituted by a group -NRi 5 Ri(5 or -N + Ri 5 Ri 6 Rn, -SO 2 -phenyl wherein such phenyl ring is optionally substituted by a group -(Ci-C 6 )alkyl NR 7 R
- R x selected from: hydrogen, (Ci-C 6 )alkyl, (Ci-C 6 )alkyl NR 7 R 8 , (Ci-C 6 )alkylphenyl wherein such phenyl ring is optionally substituted by a group (Ci-C 6 )alkylNRi 5 Ri 6 or by a group -(Cr C 6 )alkylN + R 15 Ri 6 Ri 7 , -(CH 2 ) n CONR 5 R 6 , -CH 2 -(CH 2 ) n NR 5 SO 2 R 6 ,, -(CH 2 ) t - (C 6 H 4 )-SO 2 (C C 4 )alkyl, and -(CH 2 ) r SO 2 (C C 4 )alkyl wherein such (C C 4 )alkyl is optionally substituted by a group -NRi 5 Ri 6 or -N + Ri 5 Ri 6 Ri 7 .
- Rx selected from: hydrogen, - (CH 2 ) n CONR 5 R 6 , -CH 2 -(CH 2 ) n NR 5 SO 2 R 6 ,, and -(CH 2 ) r SO 2 (C C 4 )alkyl wherein such (C 1 -C 4 )alkyl is optionally substituted by a group -N 15 i 6 or -N + R 15 Ri 6 Ri 7.
- R 14 is -COXR 3 X is oxygen, R 2 is hydrogen, A is CH and the other groups are as above defined.
- R 14 is -COXR 3 , X is NH, R 2 is hydrogen, A is CH and the other groups are as above defined.
- a compound of formula (IE) which is a compound of formula (I), wherein R 14 is a group -CN, ; R 2 is hydrogen, A is CH and the other groups are as above defined.
- a compound of the invention is selected in the group consisting of:
- a compound of the invention is selected in the group consisting of:
- the therapeutic utility of the present compounds is pertinent to any disease that is known to be at least partially mediated by the action of human neutrophil elastase.
- the present compounds may be beneficial in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), bronchiectasis, acute respiratory distress syndrome (ARDS), pulmonary emphysema, pneumonia and lung fibrosis.
- COPD chronic obstructive pulmonary disease
- CF cystic fibrosis
- ARDS acute respiratory distress syndrome
- pulmonary emphysema pneumonia and lung fibrosis.
- Compounds of the invention are useful for treatment of inflammatory respiratory disorders, for example asthma (mild, moderate or severe), steroid resistant asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoidosis, pulmonary emphysema, silicosis, pulmonary fibrosis, pulmonary hypertension, respiratory failure, acute respiratory distress syndrome (ARDS), emphysema, chronic bronchitis, tuberculosis, aspergillosis and other fungal infections, hypersensitivity pneumonitis, vasculitic and thrombotic disorders of the lung vasculature, antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, infection due to respiratory syncytial virus, influenza, coronavirus (including severe acute respiratory syndrome, SA S) and adenovirus, bronchiectasis
- the present invention is also concerned with pharmaceutical formulations comprising, as an active ingredient, a compound of the invention.
- Other compounds may be combined with compounds of this invention for the prevention and treatment of inflammatory diseases of the lung.
- the present invention is also concerned with pharmaceutical compositions for preventing and treating inflammatory diseases of the lung comprising a therapeutically effective amount of a compound of the invention and one or more other therapeutic agents.
- Suitable therapeutic agents for a combination therapy with compounds of the invention include: (1) a corticosteroid, for example budesonide, beclomethasone, beclomethasone (e.g., as the mono or the dipropionate ester), flunisolide, fluticasone (e.g. as the propionate or furoate ester), Ciclesonide, mometasone (e.g.
- Steroid drugs can additionally include steroids in clinical or pre-clinical development for respiratory diseases such as GW- 685698, GW-799943, GSK 870086, QAE397, NCX- 1010, NCX-1020, NO- dexamethasone, PL-2146, NS-126 (formerly ST- 126).
- respiratory diseases such as GW- 685698, GW-799943, GSK 870086, QAE397, NCX- 1010, NCX-1020, NO- dexamethasone, PL-2146, NS-126 (formerly ST- 126).
- Steroid drugs can also additionally include next generation molecules in development with reduced side effect profiles such as selective glucocorticoid receptor agonists (SEGRAs), including ZK-216348 and AZD5423; (2) a 2-adrenoreceptor agonist, such as albuterol, bambuterol, terbutaline, fenoterol, formoterol, formoterol fumarate, salmeterol, salmeterol xinafoate, arformoterol, arfomoterol tartrate, indacaterol (QAB-149), carmoterol, BI 1744 CL, GSK159797 (milveterol), GSK59790, GSK159802, GSK642444 (vilanterol), GSK678007, GSK96108, clenbuterol, procaterol, bitolterol, LAS 100977 (abediterol), BI1744CL (olodaterol) and brodxaterol; (3) a le
- a peptide mucolytic for example recombinant human deoxyribonoclease I (dornase-alfa and rhDNase) or helicidin
- antibiotics for example azithromycin, tobramycin and aztreonam
- MAP Mitogen Activated Protein
- MAP Mitogen Activated Protein
- kinase inhibitors such as GSK 856553 and GSK 681323
- JNK Janus Kinases
- SYK Spleen Tyrosine Kinase
- anti-retroviral agents such as ribavirin, zanamivir or
- the invention provides for the use of inhaled administration of compounds of the invention in combination with other anti- inflammatory drugs and bronchodilator drug combinations (i.e. triple combination product), including but not limited to salmeterol xinafoate/fluticasone propionate (Advair/Seretide®), formoterol fumarate/budesonide (Symbicort®), formoterol fumarate/mometasone furoate, formoterol fumarate/beclometasone dipropionate (Foster®), formoterol fumarate/fluticasone propionate (FlutiForm®), Indacaterol/mometasone furoate, Indacaterol/QAE-397, GSK159797/GSK 685698, GSK159802/GSK 685698, GSK642444/GSK 685698, formoterol fumarate/ciclesonide, arformoterol tartrate/ciclesonide, ar
- the invention provides for the use of inhaled administration of compounds of the invention in combination with other bronchodilator drug combinations, particularly B2 agonist/M3 antagonist combinations (i.e. triple combination product), including but not limited to salmeterol xinafoate/tiotropium bromide, formoterol fumarate/tiotropium bromide, BI 1744 CL/tiotropium bromide, indacaterol/NVA237, indacterol/QAT-370, formoterol/ LAS34273, GSK159797/GSK 573719, GSK159802/GSK 573719, GSK642444/GSK 573719, GSK159797/GSK 233705, GSK159802/GSK 233705, GSK642444/GSK 233705.
- B2 agonist/M3 antagonist combinations i.e. triple combination product
- the weight ratio of the first and second active ingredients may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
- prophylactic or therapeutic dose of a compound of the invention will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound and its route of administration, and will generally be determined by clinical trial as required in the pharmaceutical art. It will also vary according to the age, weight and response of the individual patient. In general, the daily dose range will lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 50 mg per kg, and most preferably 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
- compositions which comprise a compound of the invention and a pharmaceutically acceptable carrier.
- composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- the pharmaceutical compositions of the invention encompass any composition made by admixing a compound of the invention, additional active ingredient(s), and pharmaceutically acceptable excipients.
- compositions of the invention comprise a compound of the invention as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.
- any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound of the present invention.
- the active compound may be administered by any convenient, suitable or effective route.
- Suitable routes of administration are known, and include oral, intravenous, rectal, parenteral, topical, ocular, nasal, buccal and pulmonary (by inhalation).
- compositions suitable for administration by inhalation are known, and may include carriers and/or diluents that are known for use in such compositions.
- the composition may contain 0.01-99% by weight of active compound.
- a unit dose comprises the active compound in an amount of 1 g to 10 mg.
- the most suitable dosage level may be determined by any known suitable method. It will be understood, however, that the specific amount for any particular patient will depend upon a variety of factors, including the activity of the specific compound that is used, the age, body weight, diet, general health and sex of the patient, time of administration, the route of administration, the rate of excretion, the use of any other drugs, and the severity of the disease to be treated.
- the active compound is preferably in the form of microparticles. They may be prepared by a variety of techniques, including spray-drying, freeze-drying and micronisation.
- a composition of the invention may be prepared as a suspension for delivery from a nebuliser or as an aerosol in a liquid propellant, for example for use in a pressurised metered dose inhaler (PMDI).
- PMDI pressurised metered dose inhaler
- Propellants suitable for use in a PMDI are known to the skilled person, and include CFC- 12, HFA-134a, HFA-227, HCFC-22 (CC12F2) and HFA-152 (CH4F2 and isobutane).
- a composition of the invention is in dry powder form, for delivery using a dry powder inhaler (DPI).
- DPI dry powder inhaler
- Microparticles for delivery by administration may be formulated with excipients that aid delivery and release.
- microparticles may be formulated with large carrier particles that aid flow from the DPI into the lung.
- Suitable carrier particles are known, and include lactose particles; they may have a mass median aerodynamic diameter of greater than 90 ⁇ .
- composition In the case of an aerosol-based formulation, a preferred composition is: Compound of the invention 24 mg / canister
- Compounds of the invention may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which present compounds are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the invention.
- a pharmaceutical composition containing such other drugs in addition to the compound of the invention is preferred.
- the pharmaceutical compositions of the invention include those that also contain one or more other active ingredients, in addition to a compound of the invention.
- the agents of the invention may be administered in inhaled form.
- Aerosol generation can be carried out using, for example, pressure-driven jet atomizers or ultrasonic atomizers, preferably using propellant-driven metered aerosols or propellant-free administration of micronized active compounds from, for example, inhalation capsules or other "dry powder" delivery systems.
- the active compounds may be dosed as described depending on the inhaler system used.
- the administration forms may additionally contain excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
- a process for the preparation of compounds of the invention (la), i.e. compounds of formula (I) wherein Ri is hydrogen and R i4 is -COXR 3 , and of compounds of the invention of formula (lb), i.e. compounds of formula (I) wherein R ! is not hydrogen and R i4 is -COXR 3 , is provided, according to general synthetic routes reported in Scheme A here below.
- Compounds of formula (IV) may be prepared from compounds of formula (III) by reaction with ethyl chloroformate in the presence of a base such as triethylamine in a solvent such as THF at a temperature of from 0°C to reflux.
- Compounds of formula (IV) may be transformed into compounds of formula (la) by heating in an appropriate solvent. Suitable conditions include the use of a solvent such as IMS and heating using microwave irradiation at a temperature of up to 150°C.
- Compounds of formula (la), which are compounds of formula (I) wherein R 14 is C(O)XR 3 and i is H, may be converted into compounds of formula (lb), which are compounds of formula (I) wherein R 14 is C(O)XR 3 , by reaction with an alkyl halide (VI) of formula Ri-X' such as an alkyl bromide in a solvent such as DMF in the presence of a base such as cesium carbonate at a temperature of from room temperature to 100°C.
- an alkyl halide (VI) of formula Ri-X' such as an alkyl bromide
- a solvent such as DMF
- a base such as cesium carbonate
- Compounds formula (VIII) may be reacted with a benzaldehyde such as 4-cyanobenzaldehyde and a acetoacetate such as ethyl acetoacetate in the presence of an acid such as TMS-polyphosphate in a solvent such as THF at a temperature of from room temperature to reflux to give compounds of formula (VII), wherein R 3 is (Ci-C 6 )alkyl and the other groups are as defined for compounds of formula (I).
- Compounds of formula (III) may be prepared from compounds of formula (VII) by reaction with an oxidizing agent such as urea hydrogen peroxide followed by in-situ treatment with hydrazine hydrate in IMS.
- protecting group designates a protective group adapted to preserve the function of the group it is bound to.
- protective groups are used to preserve amino, hydroxyl, or carboxyl functions.
- Appropriate protecting groups may thus include, for example, benzyl, benzyloxycarbonyl, t- butoxycarbonyl, alkyl or benzyl esters or the like, which are well known [see, for a general reference, T.W. Green; Protective Groups in Organic Synthesis (Wiley, N.Y. 1981)].
- Optional salification of the compounds of formula (I) may be carried out by properly converting any of the free acidic or amino groups into the corresponding pharmaceutically acceptable salts.
- the operative conditions being employed for the optional salification of the compounds of the invention are all within the ordinary knowledge of the skilled person.
- the diastereoisomers of compounds of formula (I), where available, may be obtained according to methods well known in the art, such as for example by preparative HPLC or by chromatographic purifications.
- a racemic mixture of compounds of formula (I) may as well be separated using preparative HPLC and a column with a chiral stationary phase, or resolved to yield individual enantiomers using methods well known in the art.
- chiral intermediates may be resolved and used to prepare chiral compounds of the invention.
- Compounds of formula (XII) can be prepared from compounds of formula (VIII) using the methods described for the synthesis of compounds (la) in Scheme A and Scheme B.
- Compounds of formula (XI) may be prepared from compounds of formula (XII) by cleavage of the benzyl ester using an appropriate method such as reduction with a catalyst such as palladium on carbon in a solvent such as IMS under an atmosphere of hydrogen.
- Compounds of formula (Id) may be prepared from compounds of formula (XI) by reaction with an alcohol or amine XH 3 such as ammonia or 2-methoxy- ethanol in the presence of a coupling agent such as HATU in a solvent such as DMF in the presence of a base such as triethylamine at a temperature of from room temperature to 80°C.
- an alcohol or amine XH 3 such as ammonia or 2-methoxy- ethanol
- a coupling agent such as HATU
- a solvent such as DMF
- a base such as triethylamine
- the acid intermediate (XI) may be prepared from compounds of formula (Ic) which are compounds of formula (I) wherein X is oxygen, 3 is methyl, A, R 2 and i are hydrogen, according to Scheme D below:
- Compounds of formula (XVII) may be obtained from compounds of formula (XI) using the methods described for the transformation of compounds of formula (la) to compounds of formula (lb) in Scheme E.
- Compounds of formula (Ih) may be prepared from compounds of formula (XVII) using the methods described for the conversion of compounds of formula (XI) to compounds of formula (Id) in Scheme C.
- Compounds of formula (la) may be transformed into compounds of formula (lb) wherein R is an methylene-linked side-chain by reaction with an alkyl halide R r X' in the presence of a base such as cesium carbonate in a solvent such as DMF at a temperature of from room temperature to 80°C.
- a base such as cesium carbonate
- a solvent such as DMF
- the transformation may be achieved by Mitsunobu reaction with an alcohol R OH.
- Typical reagents employed are triphenyl phosphine and DIAD in a solvent such as THF.
- i Aryl or heteroaryl a similar transformation may be achieved by the use of a Chan-Lam coupling reaction.
- Typical reaction conditions consist of the use of a boronic acid derivative, a copper catalyst such as copper acetate, a base such as triethylamine and a solvent such as pyridine at a temperature of from room temperature to reflux.
- the transformation may be achieved by reaction of an aryl bromide with sodium methane sulfinite in the presence of a catalyst such as copper triflate, a ligand such as trans-cyclohexanediamine in a solvent such as DMSO at a temperature of up to 150°C.
- a catalyst such as copper triflate
- a ligand such as trans-cyclohexanediamine
- a solvent such as DMSO
- Typical conditions could involve heating a tertiary amine in a solvent such as ethanol or THF at elevated temperatures of between 60°C and 150°C, using microwave irradiation.
- a solvent such as ethanol or THF
- the transformation of compounds of formula (XIX) to compounds of formula (Ig) may be achieved via the tertiary amine (If) where R 9/7 and R 10 /8 ⁇ H.
- Tertiary amine compounds of formula (Ig) may be prepared from compounds of formula (XIX) by reaction with a secondary amine R 9/7 Rio /8 NH.
- Typical reaction conditions include the use of a base such as cesium carbonate or potassium carbonate in a solvent such as DMF at RT.
- the conversion of compounds of formula (If), where R 9/7 and R 10 /8 ⁇ H, to compounds of formula (Ig) can be obtained using methylating agents such as methyl bromide, methyl iodide or methyl benzenesulfonate.
- Typical reaction conditions consist of the use of a solvent such as MeCN or acetone at a temperature of between T to 60°C under conventional or microwave heating.
- primary and secondary amine compounds of formula (If) may also be prepared from compounds of formula (XIX) by reaction with ammonia or a suitable primary amine R 9/7 NH 2 , respectively to give a primary amine or secondary amine.
- 'Isolute SPE Si cartridge' refers to a pre-packed polypropylene column containing unbonded activated silica with irregular particles with average size of 50 ⁇ and nominal 6 ⁇ porosity.
- Isolute® SCX-2 cartridge refers to a pre-packed polypropylene column containing a non end-capped propylsulphonic acid functionalised silica strong cation exchange sorbent.
- PE-AX cartridge' refers to a pre-packed polypropylene column containing a silica-based sorbent with a chemically bonded quaternary ammonium functional group. All solvents and commercial reagents were used as received.
- Microwave experiments were carried out using a Biotage Initiator 60TM which uses a single-mode resonator and dynamic field tuning. Temperature from 40-250°C can be achieved, and pressures of up to 30 bar can be reached.
- MS ionisation method Electrospray (positive and negative ion)
- MS ionisation method Electrospray (positive and negative ion)
- Example 9 (160 mg, 0.36 mmol) was dissolved in DMF (5 mL) and then diisopropylethylamme (123 ⁇ ⁇ , 0.72 mmol) was added followed by HATU (280 mg, 0.72 mmol). After 1 hour, ammonia (0.5 M in dioxane, 4.3 mL, 2.15 mmol) was added and the mixture stirred at 60°C for 16 hours. The mixture was allowed to cool to T then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 0-10% MeOH in DCM to yield the title compound as a white solid (120 mg).
- Example 1 (228 mg, 0.5 mmol) was dissolved in DMF (5 mL) and cesium carbonate (652 mg, 2 mmol) and ⁇ , ⁇ '-dibromo-p-xylene (396 mg, 1.5 mmol) were added. The reaction mixture was stirred at RT for 1 hour and was then partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with 40% EtOAc in cyclohexane as eluent to give the title compound as a white solid (21 1 mg).
- Example 1 (108 mg, 0.24 mmol) was dissolved in DMF (2 mL) and cesium carbonate (94 mg, 0.29 mmol) and methyl bromoacetate (24 ⁇ , 0.26 mmol) were added. The reaction mixture was stirred at RT for 2 hours and then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 0-30% EtOAc in DCM and to yield the title compound as a white solid (1 12 mg).
- Example 1 (0.2 g, 0.44 mmol) was dissolved in DMF (4 mL) and cesium carbonate (0.19 g, 0.53 mmol) was added, followed by (3-iodo-propyl)-methyl-carbamic acid tert-butyl ester (0.14 g, 0.48 mmol). The reaction mixture was stirred at RT for 18 hours and then quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 0-5% MeOH in DCM to yield the title compound as a white solid (238 mg).
- Example 1 (228 mg, 0.5 mmol) was dissolved in THF (5 mL) and then
- Example 7 (227 mg, 0.5 mmol) was dissolved in DMF (4 mL) and cesium carbonate (195 mg, 0.6 mmol) and methyl bromoacetate (51 ⁇ , 0.55 mmol) were added. The reaction mixture was stirred at RT for 18 hours and then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with 50% EtOAc in cyclohexane to yield the title compound as a colourless glass (244 mg).
- Example 7 (455 mg, 1 mmol) was dissolved in DMF (5 mL) and cesium carbonate (489 mg, 1.5 mmol) and a solution of Intermediate 24 (481 mg, 1.3 mmol) were added. The reaction mixture was stirred at RT for 16 hours and then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with 50% EtOAc in cyclohexane to yield the title compound as an off-white foam (623 mg).
- Example 1 (85 mg, 0.19 mmol) was dissolved in DMF (3 mL) and cesium carbonate (94 mg, 0.29 mmol) and 2-iodoacetamide (41 mg, 0.22 mmol) were added. The reaction mixture was stirred at RT for 3 hours and then partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with EtOAc to give the title compound as a pale yellow solid (49 mg).
- Example 1 (85 mg, 0.19 mmol) was dissolved in DMF (3 mL) and cesium carbonate (156 mg, 0.48 mmol) and 3-dimethylamin-l -propylchloride hydrochloride (35 mg, 0.22 mmol) were added. The reaction mixture was stirred at RT for 16 hours and then heated at 65°C for 3 hours. The reaction mixture was allowed to cool and then partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 4-10% MeOH in DCM to yield the title compound as an off-white solid (23 mg).
- Example 5 was prepared from Intermediate 7 using an analogous method to that described above for Example 4 to yield the title compound as a white powder.
- Example 7 (1 12 mg) was prepared from Intermediate 1 1 (376 mg) according to an analogous procedure to that described for Example 1.
- Example 7 could be made from Example 1 by submitting Example 1 to preparative HPLC chromatography on a chiral phase [Daicel Chiralpak IC column (5 ⁇ , 250 mm x 10 mm, 3% IPA/DCM eluent, 5 ml/min flow rate, 220 nm detection)].
- Example 1 (3.15 g) was dissolved in 3% IPA/DCM (60 ml) and run with 60 injections of 1 ml to give the ( ) enantiomer (2nd eluting enantiomer) (1.5 g).
- Example 1 (60 mg, 0.13 mmol) was dissolved in DMF (1 mL) and cesium carbonate (51 mg, 0.16 mmol) and 2-chloro-N,N-dimethylacetamide (15 ⁇ , 0.15 mmol) were added. The reaction mixture was stirred at T for 16 hours and then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with 50% EtOAc in DCM to give the title compound as a white solid (56 mg).
- Example 1 (100 mg, 0.22 mmol) was dissolved in DCM (2 mL) under an atmosphere of N 2 and cooled to -78°C before the dropwise addition of BBr 3 (1M in DCM, 1 mL, 1 mmol). The reaction mixture was stirred at -78°C for 1 hour, before warming to 0°C and stirring for a further 4 hours. The reaction mixture was cautiously quenched with saturated aqueous NaHCO 3 and then diluted with DCM. The aqueous layer was separated, acidified to pH 1 by addition of 6 N HC1 and then extracted with DCM. The combined extracts were concentrated in vacuo to yield the title compound as a white solid (53 mg).
- Example 9 A solution of Example 9 (32 mg, 0.073 mmol) in DMF (1 mL) was added with diisopropylethylamme (125 ⁇ L, 0.73 mmol) followed by HATU (30 mg, 0.080 mmol). After 1 hour, N,N-dimethylethanolamine (73 ⁇ L, 0.73 mmol) was added and the reaction mixture was stirred at RT for 16 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by reverse phase HPLC using a gradient 20-70% acetonitrile in water with 0.1% ammonia to yield the title compound as a white solid (4 mg).
- Example 9 A solution of Example 9 (42 mg, 0.095 mmol) in DMF (1 mL) was added with diisopropylethylamine (33 ⁇ ⁇ , 0.19 mmol) followed by HATU (72 mg, 0.19 mmol). After 1 hour, N, N-dimethylpropanolamine (67 ⁇ ⁇ , 0.57 mmol) was added and the reaction mixture was stirred at 60°C for 16 hours. The reaction mixture was allowed to cool to RT then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 0-6% (2 M NH 3 in MeOH) in DCM to give the title compound as a white solid (15 mg).
- Example 9 A solution of Example 9 (100 mg, 0.23 mmol) in DMF (3 ml) was added with DIPEA (102 L, 0.6 mmol) and HATU (133 mg, 0.35 mmol) and the reaction mixture was stirred at T for 45 mins. Ethylamine (2 M in THF, 175 iL, 0.35 mmol) was then added and stirring at RT was continued for 16 hours. Further ethylamine (2 M in THF, 175 L, 0.35 mmol) was added, the temperature was raised to 60°C and stirring was continued for 1.5 hours. The reaction mixture was partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 80- 100% EtOAc in cyclohexane to yield the title compound as a white solid (53 mg).
- Example 1 (68 mg, 0.15 mmol) was dissolved in DCM (3 mL) and 4- methansulfonylphenyl boronic acid (90 mg, 0.45 mmol), copper (II) acetate (54 mg, 0.3 mmol), triethylamine (105 L, 0.75 mmol), pyridine (48 L, 0.6 mmol) and powdered 4A sieves (100 mg) were added. The reaction mixture was stirred at RT for 72 hours and was then filtered and the filtrate collected and evaporated in vacuo.
- Example 1 (68 mg, 0.15 mmol) was dissolved in THF (2 mL) under an atmosphere on N 2 and 3-(methylsulfonyl)-l -propanol (25 mg, 0.18 mmol) and triphenylphosphine (47 mg, 0.18 mmol) were added followed by dropwise addition of DIAD (35 ⁇ L, 0.18 mmol) in THF (200 ⁇ L).
- Example 7 (65 mg, 0.14 mmol) was dissolved in DMF (3 mL) and cesium carbonate (91 mg, 0.28 mmol) and 4-methylsulfonylbenzyl bromide (50 mg, 0.2 mmol) were added. The reaction mixture was stirred at RT for 3 hours and then partitioned between EtOAc and water. The organic layer was separated, washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with 80% EtOAc in cyclohexane to yield the title compound as a white solid (73 mg).
- Example 18 (85 mg) was prepared from Example 7 (91 mg, 0.25 mmol) and Intermediate 14 (50 mg, 0.25 mmol) according to an analogous procedure to that described for Example 17.
- Example 1 (68 mg, 0.15 mmol) was dissolved in THF (2 mL) and cesium carbonate (81 mg, 0.25 mmol) and 4-(bromomethyl)-benzenesulfonyl chloride (49 mg, 0.18 mmol) were added. The reaction mixture was stirred at T for 1 hour and then evaporated in vacuo. The resulting residue was re- dissolved in DMF (1 mL) and stirred at RT for a further 2 hours. ⁇ , ⁇ , ⁇ '- Trimethylethylenediamine (64 ⁇ ,, 0.5 mmol) was added and stirring at RT was continued for 5 hours.
- Example 7 (54 mg, 0.12 mmol) was dissolved in DMF (3 mL) and cesium carbonate (59 mg, 0.18 mmol) and l-(2-bromoethyl)-4- (methylsulfonyl)benzene (39 mg, 0.15 mmol) were added. The reaction mixture was stirred at RT for 16 hours, then the temperature was raised to 70°C and stirring was continued for 3 hours. The reaction mixture was allowed to cool to RT, then further cesium carbonate (59 mg, 0.18 mmol) and l-(2-bromoethyl)-4-(methylsulfonyl)benzene (39 mg, 0.15 mmol) were added.
- Example 1 (50 mg, 0.1 1 mmol) was dissolved in DMF (1 mL) and cesium carbonate (43 mg, 0.13 mmol), 2-chloromethyl-5-methanesulfonyl- pyridine (25 mg, 0.12 mmol) and sodium iodide (2 mg, 0.01 1 mmol) were added.
- the reaction mixture was stirred at T for 16 hours and then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo. The resulting residue was purified by silica gel chromatography eluting with a gradient of 0-50% EtOAc in DCM to yield the title compound as a white solid (41 mg).
- Example 1 (35 mg, 0.08 mmol) was dissolved in THF (2 mL) and N-(3- hydroxypropyl)-2-pyrrolidone (12 ⁇ ,, 0.09 mmol) and triphenylphosphine (59 mg, 0.22 mmol) were added followed by diethyl azodicarboxylate (42 ⁇ ,, 0.27 mmol). The reaction mixture was stirred at T for 2 hours and was then partitioned between EtOAc and water. The organic layer was separated, and the aqueous layer further extracted with EtOAc. The combined organic layers were washed with brine, dried (Na 2 SO 4 ) and evaporated in vacuo.
- the resulting residue was purified by silica gel chromatography eluting with a gradient of 0-10% MeOH in DCM. Further purification was carried out by reverse phase HPLC using a gradient of 50-98% MeOH in water + 0.1 % formic acid to yield the title compound as a white solid (10 mg).
- Example 25 (28 mg, 0.05 mmol) was dissolved in acetonitrile (0.5 mL) and then methyl bromide (23 ⁇ ⁇ of 30% solution in acetonitrile, 0.07 mmol) was added. The reaction mixture was stirred at RT for 5 days and during this period methyl bromide (50 ⁇ .) was added every 12 hours. Potassium carbonate (20 mg) was then added to the reaction mixture and stirring was continued for 12 hours. The reaction mixture was filtered and the filtrate evaporated in vacuo to yield the title compound as a white solid
- Example 26 (32 mg, 0.05 mmol) was dissolved in acetonitrile (0.5 mL) and then methyl bromide (25 ⁇ of 30% solution in acetonitrile, 0.07 mmol) was added. The reaction mixture was stirred at T for 3 days and during this period methyl bromide (25 ⁇ .) was added every 12 hours. The reaction mixture was filtered and the filtrate evaporated in vacuo to yield the title compound as a white solid (36 mg).
- Example 29 (21 mg, 0.03 mmol) was dissolved in a 30% methyl bromide in acetonitrile solution (1 mL) and potassium carbonate (30 mg) was added. The reaction mixture was stirred at RT for 3 days and then filtered and the filtrate evaporated in vacuo to yield the title compound as a white solid (25 mg).
- Example 30 (34 mg, 0.05 mmol) was dissolved in a 30% methyl bromide in acetonitrile solution (1 mL) and then potassium carbonate (30 mg) was added. The reaction mixture was stirred at T for 24 hours and then filtered and evaporated in vacuo to yield the title compound as a white solid (37 mg).
- the resulting residue was purified by silica gel chromatography eluting with a gradient of 4-8% (2 M NH 3 in MeOH) in DCM followed by a gradient of 6- 7% (2 M NH 3 in MeOH) in DCM.
- the resulting residue was purified by MDAP to yield the title compound as an off- white solid (88 mg).
- Example 33 (88 mg, 0.14 mmol) was dissolved in a 30% methyl bromide in acetonitrile solution (2 mL) and then potassium carbonate (39 mg) was added. The reaction mixture was stirred at RT for 24 hours and then filtered and evaporated in vacuo and dissolved in water. The resulting solution was eluted through Amberlite IRA458 resin and freeze dried to give the title compound as a white solid (49 mg).
- Example 39 (89 mg) was prepared from Example 14 (331 mg, 0.78 mmol) and Intermediate 20 (296 mg, 1 mmol) according to analogous procedures to those described for Intermediate 23 then Example 37.
- HNE human neutrophil elastase
- Assays were performed in 96-well plates in a total assay volume of 100 ⁇ .
- the final concentration of elastase enzyme human leukocyte elastase, Sigma E8140 was 0.0036 units/well or 0.00072 U/mL.
- the peptide substrate (MeOSuc-Ala-Ala-Pro-Val-AMC, Calbiochem #324740) was used at a final concentration of 100 ⁇ .
- the final concentration of DMSO was 1 % in the assay buffer (0.05M Tris.HCl, 0.1M NaCl, 0.1M CaCl 2 , 0.0005% brij-35, pH 7.5).
- the enzymatic reaction was started by addition of the enzyme and incubated at 25°C for 30 minutes.
- soybean trypsin inhibitor Sigma T9003
- Fluorescence was measured using a Molecular Devices fluorescence plate reader using 380 nm excitation and 460 nm emission wavelengths.
- HNE enzyme inhibition (IC 50 values) are indicated as follows: > 500 nM '+'; 100-500 nM '++'; 20-100 nM '+++'; ⁇ 20 nM '++++'.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147005526A KR20140060513A (en) | 2011-09-14 | 2012-09-12 | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
RU2014109451A RU2622643C2 (en) | 2011-09-14 | 2012-09-12 | Tetrahydrotriazolopyrimidine derivatives as inhibitors of human neutrophil elastase |
EP12769346.3A EP2766366B1 (en) | 2011-09-14 | 2012-09-12 | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors |
BR112014005669A BR112014005669A2 (en) | 2011-09-14 | 2012-09-12 | compound, pharmaceutical composition and use of a compound |
CN201280044771.XA CN103827117B (en) | 2011-09-14 | 2012-09-12 | Tetrahydrochysene triazolopyrimidine derivative as people's inhibitors of neutrophil elastase |
CA2848557A CA2848557A1 (en) | 2011-09-14 | 2012-09-12 | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11181201 | 2011-09-14 | ||
EP11181201.2 | 2011-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013037809A1 true WO2013037809A1 (en) | 2013-03-21 |
Family
ID=46982534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/067810 WO2013037809A1 (en) | 2011-09-14 | 2012-09-12 | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
Country Status (10)
Country | Link |
---|---|
US (2) | US8691826B2 (en) |
EP (1) | EP2766366B1 (en) |
KR (1) | KR20140060513A (en) |
CN (1) | CN103827117B (en) |
AR (1) | AR087841A1 (en) |
BR (1) | BR112014005669A2 (en) |
CA (1) | CA2848557A1 (en) |
RU (1) | RU2622643C2 (en) |
TW (1) | TWI568735B (en) |
WO (1) | WO2013037809A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015091281A1 (en) * | 2013-12-16 | 2015-06-25 | Chiesi Farmaceutici S.P.A. | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
WO2015188866A1 (en) * | 2014-06-12 | 2015-12-17 | Chiesi Farmaceutici S.P.A. | Novel compounds |
WO2017102674A1 (en) | 2015-12-14 | 2017-06-22 | Chiesi Farmaceutici S.P.A. | Novel tetrahydrotriazolopyrimidine derivatives as nhe inhibitors |
WO2020088984A1 (en) | 2018-10-30 | 2020-05-07 | Chiesi Farmaceutici S.P.A. | Apparatus to administer drugs to mechanically ventilated patients |
WO2021053058A1 (en) | 2019-09-17 | 2021-03-25 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
WO2021058454A1 (en) | 2019-09-24 | 2021-04-01 | Chiesi Farmaceutici S.P.A. | Novel carrier particles for dry powder formulations for inhalation |
WO2021209740A1 (en) | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
WO2023067103A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2766366B1 (en) * | 2011-09-14 | 2016-11-09 | Chiesi Farmaceutici S.p.A. | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors |
SI2935274T1 (en) * | 2012-12-18 | 2018-12-31 | Chiesi Farmaceutici S.P.A. | 3-oxo-2,3,5,8-tetrahydro-(1,2,4)triazolo(4,3-a)pyrimidine derivatives for the treatmetn of respiratory diseases |
US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9487528B2 (en) | 2014-06-09 | 2016-11-08 | Chiesi Farmaceutici S.P.A. | Compounds |
US9440930B2 (en) | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
KR20200020210A (en) | 2018-08-16 | 2020-02-26 | 서울대학교산학협력단 | Composition for inhibition of neutrophil elastase comprising plant extract |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0505321A2 (en) | 1991-03-21 | 1992-09-23 | Ciba-Geigy Ag | Inhaler |
WO2006082412A2 (en) | 2005-02-03 | 2006-08-10 | Argenta Discovery Limited | Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors |
WO2011110859A1 (en) | 2010-03-12 | 2011-09-15 | Pulmagen Therapeutics (Inflammation) Limited | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
WO2011110858A1 (en) | 2010-03-12 | 2011-09-15 | Pulmagen Therapeutics (Inflammation) Limited | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7566723B2 (en) * | 2002-09-10 | 2009-07-28 | Bayer Healthcare Ag | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
TWI334868B (en) * | 2003-06-03 | 2010-12-21 | Nippon Kayaku Kk | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof |
ATE480543T1 (en) * | 2006-05-04 | 2010-09-15 | Pulmagen Therapeutics Inflamma | TETRAHYDROPYRROLOPYRIMIDIINDIONE AND THEIR USE AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE |
GB0608844D0 (en) * | 2006-05-04 | 2006-06-14 | Argenta Discovery Ltd | Enzyme inhibitors |
DE102009004197A1 (en) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclic fused diaryldihydropyrimidine derivatives and their use |
WO2010096722A1 (en) * | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
EP2766366B1 (en) * | 2011-09-14 | 2016-11-09 | Chiesi Farmaceutici S.p.A. | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors |
-
2012
- 2012-09-12 EP EP12769346.3A patent/EP2766366B1/en active Active
- 2012-09-12 KR KR1020147005526A patent/KR20140060513A/en not_active Application Discontinuation
- 2012-09-12 WO PCT/EP2012/067810 patent/WO2013037809A1/en active Application Filing
- 2012-09-12 RU RU2014109451A patent/RU2622643C2/en not_active IP Right Cessation
- 2012-09-12 CN CN201280044771.XA patent/CN103827117B/en not_active Expired - Fee Related
- 2012-09-12 CA CA2848557A patent/CA2848557A1/en not_active Abandoned
- 2012-09-12 BR BR112014005669A patent/BR112014005669A2/en not_active IP Right Cessation
- 2012-09-12 TW TW101133256A patent/TWI568735B/en not_active IP Right Cessation
- 2012-09-12 AR ARP120103349A patent/AR087841A1/en unknown
- 2012-09-13 US US13/613,952 patent/US8691826B2/en not_active Expired - Fee Related
-
2014
- 2014-02-11 US US14/177,469 patent/US9023855B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0505321A2 (en) | 1991-03-21 | 1992-09-23 | Ciba-Geigy Ag | Inhaler |
WO2006082412A2 (en) | 2005-02-03 | 2006-08-10 | Argenta Discovery Limited | Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors |
WO2011110859A1 (en) | 2010-03-12 | 2011-09-15 | Pulmagen Therapeutics (Inflammation) Limited | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
WO2011110858A1 (en) | 2010-03-12 | 2011-09-15 | Pulmagen Therapeutics (Inflammation) Limited | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
Non-Patent Citations (6)
Title |
---|
BIETH, G.: "Regulation of Matrix accumulation", 1986, ACADEMIC PRESS, pages: 217 - 306 |
CHURG, A. ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 168, 2003, pages 199 - 207 |
LAURRELL, C.B.; ERIKKSON, S, SCAND. J. CLIN. INVEST., vol. 15, 1963, pages 132 - 140 |
T.W. GREEN: "Protective Groups in Organic Synthesis", 1981, WILEY |
THOMPSON, A.B.; DAUGHTON, D. ET AL., AM. REV. RESPIR. DIS., vol. 140, 1989, pages 1527 - 1537 |
WRIGHT, J.L. ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 166, 2002, pages 954 - 960 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015091281A1 (en) * | 2013-12-16 | 2015-06-25 | Chiesi Farmaceutici S.P.A. | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
CN105873933A (en) * | 2013-12-16 | 2016-08-17 | 奇斯药制品公司 | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors |
US9573955B2 (en) | 2013-12-16 | 2017-02-21 | Chiese Farmaceutici S.P.A. | Compounds |
WO2015188866A1 (en) * | 2014-06-12 | 2015-12-17 | Chiesi Farmaceutici S.P.A. | Novel compounds |
US9868740B2 (en) | 2014-06-12 | 2018-01-16 | Chiesi Farmaceutici S.P.A. | Pyrimidinone compounds which are HNE inhibitors |
WO2017102674A1 (en) | 2015-12-14 | 2017-06-22 | Chiesi Farmaceutici S.P.A. | Novel tetrahydrotriazolopyrimidine derivatives as nhe inhibitors |
US9890169B2 (en) | 2015-12-14 | 2018-02-13 | Chiesi Farmaceutici S.P.A. | Triazolinone compounds as HNE inhibitors |
WO2020088984A1 (en) | 2018-10-30 | 2020-05-07 | Chiesi Farmaceutici S.P.A. | Apparatus to administer drugs to mechanically ventilated patients |
WO2021053058A1 (en) | 2019-09-17 | 2021-03-25 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
WO2021058454A1 (en) | 2019-09-24 | 2021-04-01 | Chiesi Farmaceutici S.P.A. | Novel carrier particles for dry powder formulations for inhalation |
WO2021209740A1 (en) | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
WO2023067103A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Also Published As
Publication number | Publication date |
---|---|
RU2014109451A (en) | 2015-10-20 |
US9023855B2 (en) | 2015-05-05 |
TW201319070A (en) | 2013-05-16 |
KR20140060513A (en) | 2014-05-20 |
EP2766366B1 (en) | 2016-11-09 |
CA2848557A1 (en) | 2013-03-21 |
RU2622643C2 (en) | 2017-06-19 |
AR087841A1 (en) | 2014-04-23 |
CN103827117A (en) | 2014-05-28 |
TWI568735B (en) | 2017-02-01 |
US20130065913A1 (en) | 2013-03-14 |
US20140179714A1 (en) | 2014-06-26 |
CN103827117B (en) | 2016-08-24 |
EP2766366A1 (en) | 2014-08-20 |
US8691826B2 (en) | 2014-04-08 |
BR112014005669A2 (en) | 2017-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2766366B1 (en) | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors | |
US9828382B2 (en) | Pyrimidinone compounds as human neutrophil elastase inhibitors | |
US9573955B2 (en) | Compounds | |
AU2017272405C1 (en) | Imidazolone compounds as human Neutrophil Elastase inhibitors | |
US9890169B2 (en) | Triazolinone compounds as HNE inhibitors | |
US9487528B2 (en) | Compounds | |
US9868740B2 (en) | Pyrimidinone compounds which are HNE inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12769346 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012769346 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012769346 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147005526 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2848557 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2014109451 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005669 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005669 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140312 |